Pharmacological Targets in Chronic Heart Failure with Reduced Ejection Fraction

Abstract

Heart failure management has been repeatedly reviewed over time. This strategy has resulted in improved quality of life, especially in patients with heart failure with reduced ejection fraction (HFrEF). It is for this reason that new mechanisms involved in the development and progression of heart failure, along with specific therapies, have been identified. This review focuses on the most recent guidelines of therapeutic interventions, trials that explore novel therapies, and also new molecules that could improve prognosis of different HFrEF phenotypes.

Keywords

• heart failure with reduced ejection fraction
• novel pharmacological targets
• trials